C-Rad’s Shares Offering


Pareto Securities acted as sole manager and bookrunner and Baker McKenzie advised C-Rad in connection with the transaction.

C-Rad completed a directed new share issue providing the company with proceeds of approximately SEK 108 million before deduction of transaction costs.

C-Rad develops innovative solutions for use in advanced radiation therapy. The net proceeds from the transaction will primarily be used to support the company’s growth, which includes investments in expanding C-Rad’s product portfolio to increase efficiency and safety within radiation therapy.

Investors in the transaction are a number of Swedish and international institutional investors, including TIN Fonder, Joh. Berenberg, Gossler & Co. KG (Berenberg), Humle Småbolagsfond and Alfred Berg Kapitalförvaltning.

The Baker McKenzie team consisted of Joakim Falkner (Picture), Ian Gulam and Per Blom.

Involved fees earner: Per Blom – Baker McKenzie; Joakim Falkner – Baker McKenzie; Ian Gulam – Baker McKenzie;

Law Firms: Baker McKenzie;

Clients: C-Rad;

Print Friendly, PDF & Email